Recent News for BIOC - Biocept, Inc.

Date Title
Apr 7 Biocept to Host Key Opinion Leader Webinar to Discuss Its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous System
Apr 1 Biocept to Host Key Opinion Leader Webinar on April 8 to Discuss its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous System
Mar 30 The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings
Mar 30 5 Stocks To Watch For March 30, 2021
Mar 30 Biocept, Inc. (BIOC) CEO Michael Nall on Q4 2020 Results - Earnings Call Transcript
Mar 29 Biocept surges as revenue and earnings beat consensus
Mar 29 Biocept: Q4 Earnings Insights
Mar 29 Biocept EPS beats by $0.41, beats on revenue
Mar 29 Biocept Reports 2020 Fourth Quarter and Full Year Financial Results
Mar 29 Earnings Scheduled For March 29, 2021
Mar 27 The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week
Mar 27 Here's Why We're Watching Biocept's (NASDAQ:BIOC) Cash Burn Situation
Mar 22 Biocept to Report 2020 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 29, 2021
Mar 19 Biocept (BIOC) Investor Presentation - Slideshow
Mar 16 3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy
Mar 9 Biocept to Participate in Three Virtual Investment Conferences in March
Mar 2 Biocept, Aegea Bio Ink COVID-19 Test Supply Agreement
Mar 2 Biocept and Aegea Biotechnologies strike supply deal for COVID-19 assay kit
Mar 2 Aegea Biotechnologies Announces Supply Agreement with Biocept for New COVID-19 Test with the Ability to Distinguish Virus Strains and Quantify Viral Load
Feb 23 Biocept Inks Research Pact With Protean BioDiagnostics For Target Selector Kit Advantages In Lung Cancer
Feb 23 Biocept and Protean Biodiagnostics to tie up in lung cancer research deal
Feb 23 Biocept and Protean BioDiagnostics Establish Research Collaboration to Demonstrate Advantages of Biocept’s Target Selector™ Assay Kit for Non-Small Cell Lung Cancer Patients
Feb 16 Study Shows Biocept’s Target Selector™ Detects Mutations in "Quantity Not Sufficient" Specimens in Non-Small Cell Lung Cancer Patients
Feb 3 Biocept Provides Update on COVID-19 Testing with More than 250,000 Samples Received
Jan 23 Loss-Making Biocept, Inc. (NASDAQ:BIOC) Expected To Breakeven In The Medium-Term
Back to the Main BIOC Page...